好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Next-generation neuroactive steroid SAGE-217 in a multiple-ascending dose study
Movement Disorders
P3 - (-)
009
Authors/Disclosures
George Nomikos
PRESENTER
No disclosure on file
Helen Colquhoun Helen Colquhoun has received personal compensation for serving as an employee of Sage Therapeutics. Helen Colquhoun has stock in Sage Therapeutics. Helen Colquhoun has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
Shane Raines Shane Raines has received personal compensation for serving as an employee of 2b Analytics, LLC.
James Doherty, PhD (Sage Therapeutics) Dr. Doherty has received personal compensation for serving as an employee of Sage Therapeutics. Dr. Doherty has received stock or an ownership interest from Sage Therapeutics.
Ethan Hoffman No disclosure on file
Abdul J. Sankoh, PhD No disclosure on file
Steve Kanes, MD, PhD (Sage Therapeutics) Dr. Kanes has received personal compensation for serving as an employee of Sage Therapeutics. Dr. Kanes has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Verge Genomics. Dr. Kanes has received intellectual property interests from a discovery or technology relating to health care.